Andros Pharmaceuticals Co (ROCO:6917) PEG Ratio: N/A (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
41 GF Score
Price NT$34.50
GF Value NT$165.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Andros Pharmaceuticals Co's PE Ratio without NRI is 0.00. Andros Pharmaceuticals Co's 5-Year EBITDA growth rate is -5.00%. Therefore, Andros Pharmaceuticals Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Andros Pharmaceuticals Co's PEG Ratio or its related term are showing as below:



ROCO:6917's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.99
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Andros Pharmaceuticals Co  (ROCO:6917) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Andros Pharmaceuticals Co PEG Ratio Related Terms


Andros Pharmaceuticals Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co PEG Ratio Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ROCO:6917 vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Andros Pharmaceuticals Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Andros Pharmaceuticals Co PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's PEG Ratio falls into.


ROCO:6917
41GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Andros Pharmaceuticals Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-5.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • PEG Ratio: N/A
  • GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score

Get the complete analysis for ROCO:6917

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.50
Price
NT$165.02
GF Value